| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1999;68:343-347
© 1999 The Society of Thoracic Surgeons
a Division of Thoracic Surgery, Department of Surgery, College of Medicine, National Taiwan University, Taipei, Taiwan
Address reprint requests to Dr Lee, Department of Surgery, National Taiwan University Hospital, No. 7 Chung-Shan South Rd, Taipei 10016, Taiwan, ROC
Background. Alterations of the P53 or Rb gene are among the most frequently observed genetic changes in primary lung cancer. Nevertheless, there has been no final conclusion on the relationship between P53 or Rb protein expression and clinico-pathological parameters in primary lung cancer. A large-scale study was performed to examine the clinicopathological and prognostic significance of P53 and Rb expressions in 207 surgically resected non-small cell lung cancer (NSCLC) patients.
Methods. Tumor specimens were obtained from 207 primary NSCLC surgically resected from January 1990 through December 1994. The avidin-biotin-peroxidase method was used to determine the expression of P53 or Rb of tumor cells using anti-P53 or anti-Rb monoclonal antibodies. The relationships between P53 or Rb protein expression and the clinicopathological parameters were analyzed.
Results. Expression of P53 or Rb protein was detected in 115 (55.6%) and 136 (65.7%) of the 207 lung tumors, respectively. P53 had significantly higher positive results in patients with regional lymph node metastasis and advanced tumor stage. Rb expression was significantly lower in lung cancers with a macro- or microscopic picture of tumor necrosis. Additionally, an inverse correlation between the expression of Rb and P53 was found. By multiple variate analysis, P53 expression and pathological stage were independent, significant prognostic factors. Further analysis demonstrated P53 expression was an independent prognostic factor in stage 1, but not in other stages.
Conclusions. P53 expression is especially useful as a prognostic factor in stage 1 lung cancer.
Related Article
Ann. Thorac. Surg. 1999 68: 348.
This article has been cited by other articles:
|
|
 |
|
  Y.-C. Lee, C.-T. Wu, S.-W. Kuo, Y.-T. Tseng, and Y.-L. Chang Significance of Extranodal Extension of Regional Lymph Nodes in Surgically Resected Non-small Cell Lung Cancer Chest, April 1, 2007; 131(4): 993 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gebitekin, A. S Bayram, B. Tunca, and S. A Balaban Clinical Significance of p53 Gene Mutation in T1-2N0 Non-Small Cell Lung Cancer Asian Cardiovasc Thorac Ann, February 1, 2007; 15(1): 35 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Burke, D. B. Flieder, D. G. Guinee, E. Brambilla, A. N. Freedman, W. P. Bennett, R. T. Jones, A. Borkowski, N. A. Caporaso, M. Fleming, et al. Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non-Small Cell Lung Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 232 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iyoda, K. Hiroshima, M. Shiba, Y. Haga, Y. Moriya, Y. Sekine, K. Shibuya, T. Iizasa, and T. Fujisawa Clinicopathological Analysis of Pulmonary Sclerosing Hemangioma Ann. Thorac. Surg., December 1, 2004; 78(6): 1928 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Raveglia, M. Mezzetti, T. Panigalli, S. Furia, L. Giuliani, S. Conforti, and S. Meda Personal Experience in Surgical Management of Pulmonary Pleomorphic Carcinoma Ann. Thorac. Surg., November 1, 2004; 78(5): 1742 - 1747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iyoda, K. Hiroshima, Y. Moriya, T. Mizobuchi, M. Otsuji, Y. Sekine, K. Shibuya, T. Iizasa, Y. Saitoh, and T. Fujisawa Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity Ann. Thorac. Surg., June 1, 2004; 77(6): 1891 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Lee, C.-T. Wu, C.-S. Chen, H.-H. Hsu, and Y.-L. Chang The significance of E-cadherin and {alpha}-, {beta}-, and {gamma}-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 502 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Goldstein Analysis of stage I lung carcinoma patients including p53 and Rb protein Ann. Thorac. Surg., May 1, 2000; 69(5): 1648 - 1649. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
